SEC Comment Letter for GSK (GSK) — Apr 13, 2017

GSK plc
Date: April 13, 2017 · CIK: 0001131399 · Accession: 0000000000-17-012820

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-217125

Date

April 13, 2017

Author

/s/ Mary Beth Breslin for

Form

UPLOAD

Company

GSK plc

Letter

Mail Stop 4546 April 13 , 2017 Simon Dingemans Chief Financial Officer GlaxoSmithKline plc 980 Great West Road, Brentford Middlesex TW8 9GS, England

Re: GlaxoSmithKline plc Registration Statement on Form F-3 Filed April 3 , 2017 File No. 333-217125

Dear Mr. Dingemans :

This is to advise you that we have not reviewed and will not review your registration statement .

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Christine Westbrook at (202) 551 -5019 with any questions.

Sincerely,
/s/ Mary Beth Breslin for

Show Raw Text

Mail Stop 4546
April 13 , 2017

Simon Dingemans
Chief Financial Officer
GlaxoSmithKline plc
980 Great West Road, Brentford
Middlesex TW8 9GS, England

Re: GlaxoSmithKline plc
  Registration Statement on Form F-3
Filed  April 3 , 2017
  File No.  333-217125

Dear Mr. Dingemans :

This is to advise you that we have not  reviewed and will not review your registration
statement .

Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please  contact Christine Westbrook  at (202) 551 -5019  with any questions.

Sincerely,

 /s/ Mary Beth Breslin for

Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

cc: Sebastian R. Sperber, Esq.
 Cleary Gottlieb Steen & Hamilton LLP

SecProbe.io